Loading...
XASX
PNV
Market cap555mUSD
Dec 05, Last price  
1.21AUD
1D
0.83%
1Q
-20.92%
Jan 2017
317.24%
Name

Polynovo Ltd

Chart & Performance

D1W1MN
XASX:PNV chart
P/E
63.26
P/S
6.57
EPS
0.02
Div Yield, %
Shrs. gr., 5y
1.13%
Rev. gr., 5y
41.85%
Revenues
127m
+23.31%
1784,36600121,910388,2010112,56560,19622,3393,277,2043,620,1266,553,85214,043,82222,156,12329,157,92441,439,83965,241,468103,192,000127,243,000
Net income
13m
+151.17%
-11,293,869-13,406,939-4,441,167-1,830,175-1,861,559-2,917,137-2,699,475-1,492,423-2,936,379-1,302,446-3,061,874-5,006,014-5,974,132-3,189,893-4,193,737-4,605,032-1,192,532-4,924,5395,261,00013,214,000
CFO
3m
-14.53%
0000000-2,325,918-2,612,850-2,567,281-3,556,419-5,161,533-6,877,961-3,369,733-402,564-248,737-2,056,633-5,933,0673,683,0003,148,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and tissue reinforcement products; NovoSorb Dermal Beta Cell Implant to host pancreatic islets in the skin; and NovoSorb drug elution depots. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.
IPO date
Nov 26, 1998
Employees
218
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑062024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT